PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026Clinical Infectious Diseases1 citations

Fosmanogepix treatment for coccidioidomycosis under an expanded access program

View Full Paper
SCStuart H. CohenPAPaul AllynFCFelicia C. Chow

Key Points

  • The research aims to evaluate the efficacy and safety of fosmanogepix in treating coccidioidomycosis.
  • Used an expanded access program to treat patients with coccidioidomycosis.
  • Monitored treatment outcomes and adverse effects over a median duration of 208 days.
  • Fosmanogepix was successful in treating 8 of 11 patients.
  • 75% efficacy noted in patients with meningitis.
  • 66% efficacy observed in patients with non-meningeal dissemination.

Abstract

Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix ("gepix"), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 75%; non-meningeal dissemination, 2/3 66%) and was well tolerated for a median treatment duration of 208 days.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cohen et al. (2026) studied this question.

synapsesocial.com/papers/69eb08ef553a5433e34b3a54https://doi.org/10.1093/cid/ciag271
Ask AI
Helpful
Bookmark
Share
View Full Paper